Braintale develops clinically validated biomarkers for assessing white matter integrity in patients with neurological conditions, enabling early diagnosis, treatment efficacy evaluation, and disease monitoring. Their technology addresses the lack of specific biomarkers in drug development for central nervous system disorders, facilitating faster and more effective therapeutic interventions.
Funding
$6.4M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Neurological conditions, affecting a significant portion of the global population, often lack specific and reliable biomarkers for assessing brain microstructure. This deficiency hinders early diagnosis, effective treatment evaluation, and timely monitoring of disease progression, leading to drug development failures and suboptimal patient care.
Solution
BrainTale offers clinically validated biomarkers designed to evaluate white matter integrity, a critical component of the brain affected by various neurological conditions. Their proprietary platform provides sensitive and easily accessible tools for identifying at-risk patients, evaluating treatment efficacy, and monitoring disease evolution. By offering a universal measure of white matter health, BrainTale aims to improve disease diagnosis, accelerate the development of disease-modifying therapies, and support informed decision-making in clinical settings. The biomarkers are non-invasive, clinically validated, and already actionable in daily clinical practice, providing physicians and drug developers with valuable insights into central nervous system disorders.
Target Audience
The primary target audience includes physicians, hospitals, and drug developers focused on demyelinating diseases, neurodegenerative diseases, aging-related conditions, and traumatic brain injuries.
Features
- Proprietary platform of clinically validated biomarkers for assessing white matter integrity
- Non-invasive and painless assessment methods suitable for routine clinical use
- Biomarkers applicable to demyelinating diseases, neurodegenerative diseases, aging-related conditions, and traumatic brain injuries
- Platform utilized by physicians, hospitals, and drug developers for improved brain care
- CE-marked and compliant with Medical Device Regulation (MDR) standards since 2022